Clinical trials: Alpha-1 Antitrypsan Deficiency
COPD, Emphysema
Study Comparing Simulect Plus Standard Immunosuppression to Standard Immunosuppression Alone for the Prevention of Acute Rejection and Bronchiolitis Obliterans in Lung Transplant
The study will evaluate the efficacy and safety of basiliximab Vs placebo as induction therapy combined with standard triple immunosuppression therapy, in the prevention of acute rejection episodes and prevention of Bronchiolitis…
- Conditions
- COPD, Emphysema, Alpha-1 Antitrypsan Deficiency
- Trial name
- NCT00188825
- Testing
- basiliximab
- Where
- Canada
- Volunteers
- 22 people
- Sponsor
- University Health Network, Toronto